Mucopolysaccharidosis Type I
Conditions
Keywords
Mucopolysaccharidosis Type I, MPS I, Gene Therapy, AAV, Adeno-associated virus
Brief summary
This study is a single-center, single-arm, non-randomized, open-label, non controlled, dose-escalation, prospective clinical trial designed to assess the safety, tolerability, and preliminary efficacy of JWK008 injection in patients with MPS I.
Detailed description
MPS I is a rare autosomal recessive disease caused by deficiency of the α-L-iduronidase (IDUA) gene, which encodes a lysosomal enzyme required for degradation of glycosaminoglycans (GAGs).While currently available therapies, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), provide clinical benefit over untreated disease progression,they still have significant limitations. ERT does not cross the blood-brain barrier and, therefore, does not treat the central nervous system (CNS) effects of the disease. And HSCT, although it can prevent cognitive decline in patients, has a high mortality rate and morbidity. The investigators have designed a novel IDUA fusion protein with the ability to cross the blood-brain barrier through the addition of the brain-targeting peptide Mtfp. On this basis, the investigators constructed an IDUA gene expression cassette for liver-targeted expression, and used a highly efficient liver-specific promoter to make the IDUA gene specifically and efficiently expressed in liver tissue, and the expressed protein can enter the central nervous system to exert therapeutic effects.
Interventions
GENETICJWK008 Single intravenous infusion administration
Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant.
Sponsors
West China Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age≥ 18 years old; 2. Diagnosis of MPS type I; 3. Be able to understand the purpose, content, and possible risks of this clinical study, voluntarily participate in and sign the informed consent form; 4. If the subject is female, her sexual partner must agree to use reliable contraception until 2 consecutive tests of vector sequence in the blood are negative; If the subject is male, the subject agrees to use reliable contraception until the semen sample is negative for 2 consecutive tests of the vector sequence. 5. Magnetic resonance imaging (MRI) of the liver mass read by the radiologist is negative.
Exclusion criteria
1. Known to be unresponsive to ERT; or those who have been treated with intrathecal or intravenous laronidase and have serious adverse reactions, such as significant infusion-related reactions (IARs) or anaphylactic shock. 2. Serum AAV5 neutralizing antibody titer is greater than 1:100. 3. Has contraindications for Corticosteroids. 4. Current treatment with systemic (intravenous or oral) immunomodulators or steroid use (topical treatments such as asthma or eczema are allowed). 5. Has contraindications for lumbar puncture. 6. When filtering, one of the following situations exists: 1. Hepatitis B surface antigen (HBsAg) is positive, and the copy number of hepatitis B virus deoxyribonucleic acid (HBV-DNA) is\>the upper limit of normal value (ULN); 2. Hepatitis C virus antibody (HCV-Ab) is positive, and the copy number of hepatitis C virus ribonucleic acid (HCV-RNA) is\>ULN; 3. Receiving antiviral treatment for hepatitis B or C; 4. The human immunodeficiency virus (HIV) test is positive and the CD4+T lymphocyte count is ≤ 200/mm3; 7. Abnormal laboratory values considered clinically significant (ALT and/or AST \>3× upper limit of normal (ULN), total bilirubin \> 1.5× ULN, serum creatinine \> 1.5× ULN, etc.). 8. Have a history of chronic infections or other chronic diseases that researchers believe pose an unacceptable risk; 9. Active severe infection or any other significant accompanying, uncontrolled medical condition(except for those caused by MPS I), including but not limited to kidney, liver, blood, gastrointestinal, endocrine, lung, nervous system, brain or mental illness, alcoholism, drug dependence, or any psychological disorder assessed by the researcher that may interfere with adherence to experimental protocol procedures or tolerance to JWK008 injection; 10. History of active malignancy within the past 5 years (non-melanotic skin cancer or carcinoma in situ of the cervix is allowed). 11. Circulating alpha-fetoprotein (AFP) is elevated or abnormal. 12. Previously received gene therapy or participated in interventional clinical studies within the past 12 weeks; 13. Pregnant or lactating females. 14. The researcher believes that the subject is not suitable to participate in any concurrent clinically significant major diseases or other situations in the study; 15. Unable or unwilling to comply with the visit and study evaluation schedule described in the clinical protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| adverse events | 5 years | Adverse events defined as the number of participants with adverse events according CTCAE 5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GAG levels in blood, urine, and cerebrospinal fluid | 5 years | Changes in GAG levels in blood, urine, and cerebrospinal fluid before and after treatment are detected by laboratory testing. |
| Six-Minute Walk Test | 5 years | The distance that the patient could withstand the fastest walking distance on flat ground within 6 minutes before and after treatment was measured |
| IDUA enzyme activity in blood and cerebrospinal fluid | 5 years | Changes in IDUA activity in blood and cerebrospinal fluid before and after treatment are detected by laboratory testing. |
| Liver and spleen size were detected by CT | 5 years | Changes in liver and spleen size were detected by CT |
| Vector shedding | 5 years | As measured by vector concentration (quantitative polymerase chain reaction to JWK008 deoxyribonucleic acid ) in CSF, serum, and urine |
| Range of the joint motion(JROM) testing by measuring ruler | 5 years | A measuring ruler was used to detect changes in the participant's range of the joint motion before and after treatment |
Countries
China
Contacts
Primary ContactXingchen Peng, Ph.D
Outcome results
None listed